Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Short term Debt (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Short term Debt for 15 consecutive years, with $3.3 million as the latest value for Q4 2024.

  • On a quarterly basis, Short term Debt fell 17.2% to $3.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $3.3 million, a 17.2% decrease, with the full-year FY2024 number at $3.3 million, down 17.2% from a year prior.
  • Short term Debt was $3.3 million for Q4 2024 at Plus Therapeutics, roughly flat from $3.3 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $11.2 million in Q1 2020 to a low of $1.6 million in Q1 2022.
  • A 5-year average of $4.6 million and a median of $4.3 million in 2023 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: plummeted 76.18% in 2022, then skyrocketed 214.49% in 2023.
  • Plus Therapeutics' Short term Debt stood at $6.3 million in 2020, then grew by 6.58% to $6.8 million in 2021, then tumbled by 76.18% to $1.6 million in 2022, then surged by 147.26% to $4.0 million in 2023, then fell by 17.2% to $3.3 million in 2024.
  • Per Business Quant, the three most recent readings for PSTV's Short term Debt are $3.3 million (Q4 2024), $3.3 million (Q3 2024), and $3.3 million (Q2 2024).